Robert Hugin
business executiveMale0.0Global Dominance: 0.00%
Robert Hugin is a former CEO of Celgene who oversaw the launch and commercialization of Revlimid. He has been a controversial figure due to the company's pricing strategies, which have drawn criticism for making the drug unaffordable for many patients.
Power0
Reach0
Collect
Not in the pool (under ¢1).
Recent news mentions
Robert Hugin, who worked as Celgene’s CEO and then executive chairman, received $51 million in total compensation from 2015 to 2017.
The price of remission | CNNCNN·
United States· 2025-05-11
United States· 2025-05-11
